Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775628 | 0.65 | POLB (0.31) | — | |
| SCHEMBL19084117 | 0.65 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL7363898 | 0.57 | TP53 (0.32) | — | |
| SCHEMBL7356915 | 0.57 | TP53 (0.32) | — | |
| SCHEMBL13827669 | 0.57 | SMN1; SMN2 (0.50) | SMN1; SMN2 | |
| SCHEMBL24643300 | 0.56 | SLC7A5 (0.30) | — | |
| SCHEMBL25427070 | 0.53 | — | — | |
| SCHEMBL3153968 | 0.53 | — | — | |
| SCHEMBL25287622 | 0.53 | — | — | |
| SCHEMBL8954735 | 0.53 | POLB (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130177531-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-11 | — | — | US | disclosed |
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | SMN1; SMN2 1890/4885 |
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | SMN1; SMN2 1890/4885 |
| US-20130177531-A1 | Inhibitors of Serine Proteases | PRSS1, SERPINB1, PRSS3 | SMN1; SMN2 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.